Table 1 Clinical characteristics of the 23 diabetic donor kidney transplant recipients
Recipients with biopsy-proven DKD (n = 6) | Recipients without DKD (n = 17) | p value | |||
|---|---|---|---|---|---|
Recipient characteristics | |||||
 Male sex†| 4 | (66.7%) | 5 | (29.4%) | 0.162 |
 Median age at transplant in years‡ | 42.5 | (32.8–44.2) | 46.7 | (36.5–52) | 0.327 |
 Pre-transplant dialysis†| 6 | (100%) | 13 | (76.5%) | 0.539 |
 Median years on dialysis‡ | 5.9 | (3.7–9.2) | 2.8 | (1.8–4.5) | 0.005** |
Cause of ESRD§ | 0.854 | ||||
 Diabetes†| 1 | (16.7%) | 4 | (23.5%) | 1.000 |
 Glomerular disease†| 2 | (33.3%) | 7 | (41.2%) | 1.000 |
 Other†| 1 | (16.7%) | 1 | (5.9%) | 0.462 |
 Unknown†| 2 | (33.3%) | 5 | (29.4%) | 1.000 |
Median BMI (kg/m2) at transplant‡ | 23.1 | (21.1–24.9) | 22.3 | (20.8–25.2) | 0.806 |
Anti-HCV (+) recipient†| 0 | (0%) | 2 | (11.8%) | 1.000 |
Post-transplant diabetes mellitus†| 0 | (0%) | 2 | (11.8%) | 1.000 |
HbA1c before transplantation (%) ‡ | 5.4 | (5.2–5.5) | 5.4 | (5.0–6.1) | 0.889 |
HbA1c after transplantation (%) ‡ | 5.9 | (5.7–5.9) | 6.0 | (5.5–6.9) | 0.674 |
Median BMI (kg/m2) at follow-up biopsy‡ | 24.8 | (21.6–26.7) | 21.7 | (20.0–25.2) | 0.183 |
Weight change (kg) after transplantation ‡ | −1.5 | (−2.7–4.6) | −1.0 | (−3.1–1.8) | 0.861 |
Overweight at follow-up biopsy†| 3 | (50.0%) | 5 | (29.4%) | 0.621 |
HbA1c≧5.7% at follow-up biopsy †| 5 | (83.3%) | 12 | (70.6%) | 1.000 |
Dyslipidemia at follow-up biopsy†| 6 | (100%) | 7 | (41.2%) | 0.019* |
Hypertension at follow-up biopsy†| 6 | (100%) | 12 | (70.6%) | 0.273 |
Last UPCR after transplantation (mg/mg) ‡ | 7.3 | (2.0–10.0) | 0.2 | (0.1–0.7) | 0.001** |
Best eGFR after transplantation (ml/min/1.73m2) ‡ | 49.0 | (42.2–85.1) | 62.9 | (53.3–81.2) | 0.294 |
Last eGFR after transplantation (ml/min/1.73m2) ‡ | 10.4 | (8.9–14.2) | 47.3 | (32.3–55.2) | 0.003** |
eGFR decline rate (ml/min/1.73m2/year) ‡ | 10.6 | (8.7–14.9) | 5.8 | (2.6–9.8) | 0.017* |
Median duration of follow-up in years‡ | 4.2 | (3.7–7.3) | 5.6 | (2.7–10.5) | 0.575 |
Graft failure†| 1 | (16.7%) | 0 | (0%) | 0.261 |
Donor characteristics | |||||
 Median donor age in years ‡ | 50.5 | (39.0–57.0) | 54.0 | (37.5–60.0) | 0.529 |
 Median BMI at transplant (kg/m2) ‡ | 26.9 | (24–28.2) | 23.9 | (22.6–30.8) | 0.506 |
 Creatinine at transplant (mg/dl) ‡ | 1.7 | (0.8–2.5) | 1.0 | (0.7–1.4) | 0.345 |
 eGFR at transplant (ml/min/1.73m2) ‡ | 60.1 | (28.4–111.6) | 84.1 | (56.3–99.8) | 0.649 |
 Last HbA1c before transplantation (%) ‡ | 7.1 | (7.0–8.1) | 6.7 | (6.3–7.1) | 0.069 |
 Anti-HCV (+) donor†| 0 | (0%) | 2 | (11.8%) | 1.000 |
 History of hypertension†| 4 | (66.7%) | 6 | (35.3%) | 0.341 |
 Expanded criteria donor†| 3 | (50%) | 7 | (41.2%) | 1.000 |
 Transplanted kidney RPS DN classification≧IIa †| 4/4a | (100%) | 0/7b | (14.3%) | 0.003* |
Transplant characteristics | |||||
 PRA≧30%†| 1 | (16.7%) | 6 | (35.3%) | 0.621 |
 ≧1 HLA mismatch†| 5 | (83.3%) | 16 | (94.1%) | 0.462 |
 Delayed graft function†| 3 | (50.0%) | 3 | (17.6%) | 0.279 |
 Acute rejection within 1 year†| 2 | (33.3%) | 4 | (23.5%) | 0.632 |
 Tacrolimus + MMF/MPA + steroid maintenance†| 5 | (83.3%) | 13 | (76.5%) | 1.000 |
 Cyclosporine + MMF/MPA + steroid maintenance†| 1 | (16.7%) | 4 | (23.5%) | 1.000 |
 No induction†| 1 | (16.7%) | 1 | (5.9%) | 0.462 |
 Lymphodepleting induction†| 2 | (33.3%) | 6 | (35.3%) | 1.000 |
 Non-lymphodepleting induction†| 3 | (50.0%) | 10 | (58.8%) | 1.000 |